Once again, Novo's semaglutide shows cardiovascular benefit, weight loss — this time in adults with heart failure
Novo Nordisk’s GLP-1 Wegovy has shown cardiovascular benefit again, this time in the Phase III STEP HFpEF trial, on top of the expected weight loss …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
